Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Oncolytics Biotech Inc. is a clinical-stage biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to registration-enabling clinical studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Comment by canadafanon Nov 14, 2023 3:05pm
156 Views
Post# 35735135

RE:RE:Institutional investor

RE:RE:Institutional investor I agree, on the dates.
the trouble with in line ," data," one must read the dates of the data posting & reporting.
which both can be different from the actual date of transaction.
regarding do they Anison still own the shares?
most likely...
how can I draw that conclusion?
since the date of purchase, that many shares has not traded ( on the TSX ), cumulatively since the deal.
volume has been dismal.
also, their motivation is to make $$. Selling at a loss ( since the deal), is not helpful for that.
I do agree 100%, Onc management needs a paradigm shift.
Matt should step aside as president. Stay on as clinical advisor & chairman.
Move Andrew up to " make ONC business focused".
Dr. Coffey has moved the ball to the Finnish line. Multiple trials & many with phase 3 ready results.
Time to bring in the business team.
I do see a deal by end of this year. Aka next few weeks.
way too many " events" have happened last 3 weeks, to be ignored.


<< Previous
Bullboard Posts
Next >>